CD274 and non-small cell lung carcinoma: Moreover, several ICIs, including pembrolizumab, nivolumab, and atezolizumab, have been approved as subsequent therapies for patients with advanced or metastatic NSCLC if they have not yet received a PD-1/PD-L1 inhibitor.